Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
68,578,543
-
Total 13F shares
-
42,840,862
-
Share change
-
+1,102,407
-
Total reported value
-
$3,599,617,322
-
Put/Call ratio
-
15%
-
Price per share
-
$84.06
-
Number of holders
-
131
-
Value change
-
+$96,210,239
-
Number of buys
-
84
-
Number of sells
-
43
Institutional Holders of Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL) as of Q4 2021
As of 31 Dec 2021 Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL) had 131 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 42,840,862 shares of stock of the company.
Largest 10 holders included FMR LLC, PRICE T ROWE ASSOCIATES INC /MD/, Matrix Capital Management Company, LP, VANGUARD GROUP INC, BlackRock Inc., Avidity Partners Management LP, TYBOURNE CAPITAL MANAGEMENT (HK) LTD, VIKING GLOBAL INVESTORS LP, STATE STREET CORP, and PRIMECAP MANAGEMENT CO/CA/.
This table shows 131 institutional shareholders of the security as of 31 Dec 2021.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.